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Objective: The need for long-term medication in diabetes mellitus has led to a search for herbal medicines as alternative treatments. Several studies 
have shown that extract or isolates of Garcinia mangostana can help prevent and treat type 2 diabetes mellitus (T2DM). 
Methods: This review was conducted by searching various databases, including PubMed, ClinicalKey, ScienceDirect, and EBSCOhost. We analyzed 
papers published within the previous 10 y. 
Results: All in vitro, in vivo, and clinical studies that evaluated the pharmacological effects of extract or isolates of G. mangostana in T2DM were 
reviewed. G. mangostana was found to suppress adipogenesis and regulate lipid homeostasis, thus improving lipid profiles and preventing T2DM. G. 
mangostana also demonstrated hypoglycemic properties, including the ability to decrease fasting blood glucose and mildly increase pancreatic β-
cell numbers and activity. The mangosteen-treated group in one study showed a decrease in Homeostatic Model Assesment for Insulin Resistance 
(HOMA-IR), indicating improved insulin sensitivity, along with a significant decrease in the high-sensitivity CRP (hs-CRP) levels. Histopathology 
showed that the α-mangostin-treated group had less damage to pancreatic β cells, healthier hepatocytes and central veins, and less glomerular and 
tubular epithelial necrosis than the diabetic control group. Moreover, the antioxidant effect of G. mangostana was shown to protect against the 
micro-and macrovascular damage caused by T2DM. 
Conclusion: Extract or isolates of G. mangostana possess strong potential to prevent and treat T2DM. Further research evaluating long-term 
outcome biomarkers in humans is needed to confirm the drug’s glycemic control capacity. 
Keywords: Garcinia mangostana, Mangosteen, α-mangostin, Type 2 diabetes mellitus 
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INTRODUCTION 
Diabetes mellitus (DM) is a hyperglycemic condition caused by 
metabolic disorders. The prevalence of DM has drastically increased 
from 30 million cases in 1985 to 224 million cases in 2014; this number 
is predicted to double in the next 30 y. In 2015, 1.6 million deaths were 
caused by diabetes [1]. The increase in cases of DM is due to our modern 
lifestyle that leads to obesity and less physical activity [2]. 
Type-2 DM is a chronic disease that requires long-term medication, 
with the associated side effects and costs. First-line medication for 
type-2 DM after lifestyle modification is metformin, followed by 
sulfonylurea. Metformin has gastrointestinal side effects whereas 
sulfonylurea causes weight gain and hypoglycemia [3]. Other side 
effects that may occur include headache, dizziness, nausea, and 
hypersensitivity reactions [4]. 
For these reasons, herbal medication has become an alternative 
treatment for DM, with fewer side effects and lower cost. Herbs that have 
shown effects in clinical trials of DM treatment include Gymnema 
sylvestre, Momordica charantia, Folium mori, Trigonella foenum-
graecum, Rhizoma coptidis, Ginkgo biloba, Radix ginseng, and Garcinia 
mangostana. Pharmacological mechanisms of these herbs include 
increasing glycogen production, stimulating insulin secretion, increasing 
glucose uptake in the peripheral tissues, increasing insulin sensitivity, 
and decreasing carbohydrate absorption [5]. 
Prevention of type-2 DM is as important as treatment and is 
significantly less expensive. Herbs that have been shown to have 
preventive effects in type-2 DM include capsaicin, chili pepper, 
Curcuma longa, Chinese tea, and genistein from soybeans [6]. 
Garcinia mangostana is a tropical fruit commonly found in Southeast 
Asia. G. mangostana has been popularly used to treat inflammation, 
skin infections, and diarrhea [7]. More than 68 xanthones have been 
identified in all parts of mangosteen. One study identified the 
chemical constituents in a dichloromethane extract of mangosteen 
seed and pulp [8]. The seed contained triacylglycerol and 
stigmasterol, while the pulp contained α-mangostin, 3-isomangostin, 
δ-tocotrienol, and vitamin E. Fifty of the 68 xanthones identified in 
mangosteen are contained in the pericarp (fruit hull). The major 
constituent in the pericarp is α-mangostin. Other constituents 
include isomangostin, mangotinone, 8-deoxygartanin, gartanin, and 
β-mangostin. Among these constituents, α-mangostin has been most 
widely studied and has shown antioxidant, anticarcinogen, 
antibacterial, and anti-inflammatory effects, as well as apoptosis 
induction potential [9]. Studies have also shown that G. mangostana 
extract can help prevent and treat type-2 DM. The aim of this review 
was to summarize the effectiveness of extracts or isolates of G. 
mangostana in the prevention and treatment of type-2 DM.  
MATERIALS AND METHODS 
We conducted a literature search of various databases, including 
PubMed, ClinicalKey, ScienceDirect, and EBSCOhost, with keywords 
“Garcinia mangostana,” “mangosteen,” “mangostin,” AND “insulin,” 
“diabetes,” “blood glucose,” “hyperglycemic.” We analyzed papers 
published within the previous 10 y. 
RESULTS AND DISCUSSION 
The pathophysiology of type-2 DM includes a series of conditions that 
lead to hyperglycemia. Obesity often leads to type-2 DM. In patients with 
obesity, the amount of adiponectin, which helps to enhance insulin 
sensitivity, decreases. Increased production of adipokines and increased 
adipocyte numbers in obesity cause inflammation, which elevates IL-6 
and C-reactive protein (CRP). The decrease in insulin sensitivity triggers 
the production of more insulin, thus creating hyperinsulinemia. At some 
point, pancreatic islet cells cannot maintain homeostasis, resulting in 
hyperglycemia [2]. 
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Insulin resistance also induces a decline in glucose utilization by 
tissues, thus creating the perception of glucose shortage in the body. 
This in turn triggers the liver to increase gluconeogenesis and 
results in fasting hyperglycemia and decreased glycogen storage in 
the liver. Insulin resistance in adipose tissue also causes lipolysis 
and increased release of free fatty acids into the circulation, thus 
enhancing very-low-density lipoprotein (VLDL) and triglyceride 
synthesis in the liver. This leads to fat accumulation in the liver and 
decreased liver function, resulting in abnormal liver function tests. 
Moreover, these conditions also contribute to dyslipidemia, 
including high triglycerides, decreased high-density lipoprotein 
(HDL), and increased low-density lipoprotein (LDL) in patients with 
type-2 DM. Dyslipidemia increases the risk of cardiovascular disease 
in patents with type-2 DM [10]. 
Hyperglycemia also generates free radicals and contributes to 
vascular disease. Free radicals damage cell membranes and can lead 
to micro-and macrovascular complications [2]. Microvascular 
complications include diabetic retinopathy, diabetic nephropathy, 
neuropathy, and decreased liver function; macrovascular 
complications include atherosclerosis [11]. One mechanism behind 
these complications is the production of advanced glycation 
products (AGEs), which are products of nonenzymatic glycation of 
plasma proteins caused by chronic hyperglycemia. These AGEs 
increase oxidative stress, inflammation, and glycation of LDL and 
HDL, and reduce nitric oxide availability, all of which lead to the 
above complications [12]. This condition also provokes alteration of 
hemodynamics in the microcirculation of the kidney, including 
glomerular hyperfiltration and increased capillary pressure in the 
glomerulus. Glomerular hyperperfusion increases the glomerular 
filtration rate and causes thickening of the glomerular basement 
membrane. After 5 to 10 y of these conditions, albuminuria will 
begin, indicating declining kidney function [2]. 
Effect on preventing type-2 diabetes mellitus in patients with 
obesity 
As stated above, obesity is often the leading cause of insulin 
resistance in patients with type-2 DM. Preventing lipid accumulation 
might help reduce the risk of insulin resistance, thus reducing the 
risk of developing type-2 DM. Ethanolic extract of G. mangosteen 
showed antiobesity effects in rats with high-fat-diet-induced obesity, 
reducing both adipose mass and weight gain [13]. The mechanism 
by which the drug reduces adipose mass was clarified in an in vitro 
study that isolated α-mangostin from the hulls of G. mangostana 
[14]. That study found that α-mangostin had cytotoxic effects against 
3T3-L1 cells through inhibition of fatty acid synthase. Inhibition of 
fatty acid synthase induces apoptosis of preadipocytes, suppresses 
adipocyte differentiation, and causes lipolysis of mature adipocytes, 
thus reducing lipid accumulation. Therefore, the authors concluded 
that the antiobesity effects of mangosteen might reduce the risk of 
insulin resistance in type-2 DM [14]. 
Effect on blood glucose 
Glycemic control is an important goal in treating type-2 DM. 
Administration of mangosteen rind extract in streptozotocin (STZ)-
induced diabetic rats at doses of 50 and 200 mg/kg BW/day for 7 d 
was shown to lower blood glucose [15]. Another study on 
administration of G. mangostana pericarp extract also showed a 
significant reduction in blood glucose levels [16] In that study, 
histopathology analysis of STZ-induced diabetic rats showed that the 
hypoglycemic effect of this extract resulted from enhancement of 
insulin secretion and peripheral utilization of insulin. This increase 
in insulin levels results from the antioxidant effects of G. 
mangostana, which causes neutralization of free radicals in the islet 
cells, thus initiating regeneration of insulin-producing β cells [16]. 
This result was supported by another in vivo study that evaluated 
the effects of α-mangostin, one of the bioactive compounds in G. 
mangostana [17]. STZ-induced diabetic rats treated with α-
mangostin showed a significant decrease in blood glucose levels at 
tested doses of 25, 50, and 100 mg/kg BW/day. A dose of 100 mg/kg 
BW/day resulted in the maximum decrease in blood glucose, along 
with a significant increase in plasma insulin level. The proposed 
mechanism of the hypoglycemic effect exerted by α-mangostin was 
protection and increased activity of pancreatic β cells, which results 
in increased insulin levels, which in turn lowers blood glucose levels. 
This hypothesis was confirmed on histopathology, where it was 
found that α-mangostin protected pancreatic β cells from the toxic 
effects of STZ [17]. 
Evaluation of the constituents of the ethanolic extract of G. 
mangostana pericarp shows that its hypoglycemic activity might be 
attributable to the polyphenols present. Polyphenols such as tannins 
and xanthones cause hypoglycemic effects by initiating β-cell 
regeneration. Moreover, an in vitro study found that tannins and 
xanthones, especially γ-mangostin, were potent natural inhibitors of 
α-amylase and α-glucosidase, and thus reduced postprandial 
hyperglycemia by suppressing glucose absorption. Hence, G. 
mangostana could help lower postprandial blood glucose levels [18]. 
Effect on inflammation 
Inflammation itself plays an important role in the development of 
type-2 DM and affects insulin sensitivity. CRP and TNF-α are markers 
of low-grade inflammation and vascular injury, whereas IL-6 can alter 
the insulin receptor, resulting in the progression of insulin resistance. 
Oral administration of α-mangostin in STZ-induced diabetic rats 
resulted in levels of inflammatory cytokines (CRP, TNF-α, and IL-6) 
decreasing to near normal in a dose-dependent manner [17]. In an 8-
week clinical study involving 40 patients with obesity, the group given 
18 oz of mangosteen juice per day showed a significant decrease in 
high-sensitivity (hs)-CRP, compared with the placebo group [19]. 
These studies show that mangosteen can decrease inflammatory 
markers such as CRP and TNF-α.  
Effect on insulin secretion and insulin resistance 
In an in vitro study, α-mangostin was shown to stimulate insulin 
secretion in rat pancreatic INS-1 cells by activating pancreatic and 
duodenal homeobox 1 and insulin receptor, followed by 
phosphorylation of phospho-phosphatidylinositol-3 kinase, Akt, and 
extracellular signal-regulated kinase-signaling cascades [20]. The 
compound also inhibited the phosphorylation of insulin receptor 
substrate. Besides enhancing insulin secretion, α-mangostin also had 
a protective effect against insulin resistance in an in vivo study in 
STZ-induced diabetic Wistar rats [17]. Another bioactive compound 
of G. mangostana, γ-mangostin, was shown to prevent insulin 
resistance induced by lipopolysaccharide, by preventing the 
suppression of PPARγ and adiponectin gene expression [21]. One 
clinical trial showed that homeostatic model assessment–insulin 
resistance (HOMA-IR) decreased significantly more in a 
mangosteen-treated group than in the control group, supporting the 
results of previous preclinical studies [22]. Insulin resistance plays a 
dominant role in the pathophysiology of type-2 DM; therefore, 
improving insulin sensitivity can help treat DM. 
Effect on hepatic function  
The liver is an important organ in regulating glucose metabolism, 
and thus plays an important role in the pathogenesis of type-2 DM. 
The liver enzymes Serum Glutamic Oxaloacetic Transaminase 
(SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), and Alkaline 
Phosphatase (ALP) are often used to examine the integrity of 
hepatocytes. Hepatocyte injury will cause these enzymes to leak into 
the bloodstream. A group of STZ-induced diabetic rats treated with 
α-mangostin showed lower levels of SGOT, SGPT, and ALP compared 
with untreated STZ-induced diabetic rats [17]. A dose-dependent 
reduction in liver enzymes was also seen in a group of rats treated 
with ethanolic extract of G. mangostana pericarp, with 100 mg/kg 
BW/day producing the greatest reduction [16]. A possible 
mechanism of this effect is that α-mangostin improves hepatocyte 
health. This effect was confirmed in a histopathology study in which 
reduced accumulation of fat droplets was seen in hepatocytes of 
STZ-induced diabetic rats treated with α-mangostin [17]. 
Other enzymes, such as hexokinase, glucose-6-phosphatase, and 
fructose-1,6-biphosphatase are also found in the liver. Unlike SGOT, 
SGPT, and ALP, these enzymes are not used to evaluate hepatocyte 
integrity, yet they play an important role in regulating glucose 
metabolism in the body. Hexokinase plays a role in converting 
glucose to glucose-6-phosphatase so that cells can utilize glucose to 
produce energy. Increased hexokinase levels can reduce blood 
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glucose and increase glucose utilization. Glucose-6-phosphatase and 
fructose-1,6-biphosphatase are enzymes that participate in 
converting glucose precursors to glucose. In STZ-induced diabetic 
rats, levels of these enzymes were found to increase whereas 
hexokinase decreased [17]. A significant dose-dependent increase in 
the level of hexokinase and decrease in the levels of glucose-6-
phosphatase and fructose-1,6-biphosphatase were found in STZ-
induced diabetic rats treated with α-mangostin. Bringing the levels 
of these enzymes into the normal range helps reduce the production 
of hepatic glucose and lowers fat deposition in the liver; these 
findings were supported by histopathology [17]. 
Glycogen is another compound found in the liver. Insulin plays an 
important role in inhibiting glycogen phosphorylase and 
maintaining glycogen storage. The inability to maintain glycogen 
storage is one aspect of liver-function impairment in DM. In STZ-
induced diabetic rats, the level of hepatic glycogen increased with 
α-mangostin treatment, indicating improved glycogen storage 
[17]. These results confirm the hepatoprotective effect of G. 
mangostana. 
Effect on lipid profile 
Reducing the risk of cardiovascular disease (CVD) is an important 
therapy goal for patients with type-2 DM because CVD is the leading 
cause of mortality in this population. Lipid profile parameters that 
are associated with CVD include triglycerides, LDL, VLDL, HDL, and 
cholesterol. In DM, triglycerides, LDL, VLDL, and cholesterol levels 
are increased. The fat metabolism disorder found in the diabetic 
condition is the cause of these elevations. STZ-induced diabetic rats 
treated with α-mangostin showed significant alterations in the lipid 
profile, which returned to near-normal or normal conditions. It is 
hypothesized that α-mangostin increases insulin levels, which 
results in hydrolysis of triglycerides and decreased lipolysis and 
fatty acid flux, thus decreasing LDL and VLDL synthesis in 
hepatocytes. Moreover, lower levels of LDL and VLDL in peripheral 
tissues enables them to excrete more HDL. These lipid-lowering 
effects thus decrease coronary risk. A dose-dependent decrease in 
the atherogenic and coronary risk index was also found in STZ-
induced diabetic rats treated with α-mangostin [17]. 
Administering ethanolic extract of G. mangostana pericarp also 
lowers triglycerides, LDL, VLDL, and total cholesterol levels [16]. 
Because ethanol is a polar solvent, this result is in line with another 
study that showed that nonpolar and semipolar fractions of 
mangosteen pericarp extract did not reduce fasting cholesterol level 
in STZ-induced diabetic rats, whereas the polar extract produced a 
significant reduction [23]. One clinical study also showed a 
significant increase in HDL cholesterol in the mangosteen-treated 
group after 26 w, indicating a protective effect against 
cardiovascular risk in patients with type-2 DM [22]. 
Effect as antioxidant  
The destructive effect of free radicals generated by hyperglycemia in 
type-2 DM plays an important role in micro-and macrovascular 
conditions. Free radicals cause lipid peroxidation and further 
damage cell membranes. Antioxidants are substances that inhibit the 
deleterious effects of free radicals, thus preventing damage to cell 
wall membranes, DNA, blood vessels, and other tissues. 
Malondialdehyde (MDA) is an end-product of lipid peroxidation and 
can thus be used as an indicator of cell or tissue damage caused by 
lipid peroxidation activity. Nonpolar, semipolar, and polar fractions 
of mangosteen pericarp extract have shown significant effects in 
decreasing serum MDA levels in rats with STZ-induced type-2 DM 
[23]. The group of diabetic rats treated with α-mangostin showed 
restoration of endogenous antioxidant enzymes to near-normal 
levels. Hepatic and renal superoxide dismutase and catalase, which 
are first-line endogenous scavenging enzymes, increased, confirming 
the antioxidant effect of α-mangostin, which acts as a free radical-
scavenging compound [17]. Xanthones from mangosteen provide 
additional antioxidants to counter the destructive effects of free 
radicals. In a study of xanthone administration, a phenolic 
compound isolated from the pericarp of G. mangostana reduced 
plasma and renal MDA levels, indicating the antioxidant effects of 
this compound [24]. 
In hyperglycemia, the process of glycation occurs. This has been 
used as a marker of oxidative stress in this condition. STZ-induced 
diabetic rats treated with α-mangostin showed decreased levels of 
glycated hemoglobin, indicating reduced oxidative stress. It is 
possible that this action of α-mangostin results from enhancement of 
endogenous antioxidant levels and reduced blood glucose. It is 
accepted that enhanced antioxidant activity prevents diabetic 
complications. 
Effect on renal function 
Reactive oxygen species generated in hyperglycemia cause lipid 
peroxidation and can injure the kidney, resulting in diabetic 
nephropathy. Renal dysfunction in STZ-induced diabetic rats is 
marked by increased levels of creatinine and blood urea nitrogen 
(BUN), with decreased levels of total protein. STZ-induced diabetic 
rats treated with α-mangostin showed decreased levels of serum 
creatinine and BUN, and increased total protein levels [17]. Rats 
treated with α-mangostin at 100 mg/kg BW/day showed more 
improvement in renal parameters than rats receiving different 
treatment doses. It has been hypothesized that α-mangostin 
decreases the protein degradation that occurs in DM. This 
hypothesis is supported by histopathology findings that show 
significant decreases in glomerular focal necrosis and tubular 
epithelial necrosis in α-mangostin-treated rats [17]. Significant 
improvement in renal markers was also seen after treatment with 
ethanolic extract and xanthone of G. mangostana pericarp as a result 
of scavenging of the free radicals generated in hyperglycemia [16, 
25] This extract improved renal parameters, supporting the above 
results on the ability of G. mangostana to ameliorate renal 
dysfunction in type-2 DM. It was thus concluded that G. mangostana 
might have renoprotective effects [17]. 
Effect on advanced glycation end-products (AGEs) and other DM 
complications 
AGEs result from nonenzymatic reactions between the amino group 
of a protein and the carbonyl group of a sugar during hyperglycemia. 
AGEs are used clinically as an indicator of short-term blood glucose 
control in diabetic patients. The accumulation and precipitation of 
AGEs in body tissues leads to several complications of chronic 
diabetes, including atherosclerosis, retinopathy, neuropathy, 
nephropathy, endothelial dysfunction, and Alzheimer’s disease [25, 
26]. Six known compounds and two new xanthones of G. 
mangostana, mangostanaxanthones III and IV, were isolated from 
methanol extract of G. mangostana pericarp. These isolated 
metabolites inhibited both sugar-and dicarbonyl compound-induced 
protein glycation. Hence, these metabolites were confirmed to have 
anti-AGE properties [25]. Moreover, four phenolic compounds 
isolated from methanol extract of G. mangostana pericarp inhibited 
AGE formation at the levels of Amadori product and protein 
aggregation by saving protein thiols [26]. 
Aldose reductase is an enzyme that plays a role in the polyol 
pathway by catalyzing the reduction of glucose to sorbitol with 
oxidation of NADPH to NADP+. Increased sorbitol is thought to play 
a role in diabetic complications, such as cardiovascular autonomic 
neuropathy. A study that used dichloromethane extract of the root 
bark of G. mangostana Linn demonstrated that its xanthones were 
potent human aldose reductase inhibitors. The most potent 
xanthone against aldose reductase was 3-isomangostin. These 
findings validated mangosteen as a potent aldose reductase 
inhibitor, indicating that it can reduce the risk of diabetic 
complications [27]. 
Summary of the effects of G. mangostana in type-2 diabetes 
mellitus 
One study compared different forms of G. mangostana and found 
that G. mangostana extract had higher bioavailability than the 
isolated pure conjugated xanthone, α-mangostin [28] A summary of 
the effects of G. mangostana in type-2 DM is shown in table 1. 
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Table 1: Summary of the effects of Garcinia mangostana in type-2 diabetes mellitus 
Study design Garcinia mangostana component/dose Results Reference 
In vitro: human 
adipocytes 
γ-mangostin Prevented LPS-mediated insulin 
resistance in human adipocytes 
Bumrungpert et 
al., 2009 
In vitro Ethanol extract of fruit hull Inhibited α-glucosidase  
↓ postprandial blood glucose level 
Ryu et al., 2011 
In vitro: 3T3-L1 cells α-mangostin from hulls Inhibited fatty acid synthase 
↑ lipolysis 
Quan et al., 
2012 
In vitro Dichloromethane extract of root bark (α-mangostin, β-
mangostin, 3-isomangostin) 
Inhibited aldose reductase Fatmawati et 
al., 2014 
In vitro Pericarp methanol extract containing 
mangostanaxanthones III and IV 
↓ advanced glycation end-product Abdallah et al., 
2017 
In vitro Phenolic compounds isolated from fruit hulls ↓ advanced glycation end-product Abdallah et al., 
2016 
In vitro: rat pancreatic 
INS-1 cells 
α-Mangostin ↑ insulin secretion Lee et al., 2018 
In vivo: STZ-induced 
male rats 
α-Mangostin; given at 25, 50, or 100 mg/kg/day orally 
for 56 d 
↓ blood glucose level;  
↑ plasma insulin level;  
↓ HOMA IR;  
↑ hexokinase; ↓ G-6-Pase; ↓ fructose-1,6-
biphosphatase; ↓ SGOT, SGPT, and ALP;  
↓ LDL and VLDL; ↑ HDL; reduced 
atherogenic and coronary risk index;  
↑ antioxidant enzymes (SOD and CAT); 
↓ glycated hemoglobin (lowering 
oxidative stress); 
↑ liver glycogen storage;  
↓ serum creatinine and BUN, ↑ total 
protein;  
↓ inflammatory cytokines (CRP, TNF-α, 
and IL-6) 
Kumar et al., 
2016 
In vivo: high fat diet-
induced for 3 w prior to 
STZ-induction male 
mice 
Pericarp extract of G. mangostana, macerated with three 
solvents: n-hexane (nonpolar fraction), chloroform 
(semipolar fraction), ethanol (polar fraction); given 
orally to three groups of mice for 14 d, dose ~100 mg/kg 
BW of crude extract 
↓ fasting blood cholesterol in polar 
fraction 
↓ MDA levels 
Husen et al., 
2016 
In vivo: high-fat diet 
male mice 
Ethanolic peel extract of G. mangostana; 50 or 200 mg/kg 
containing 25.7% α-mangostin and 3.8% γ-mangostin  
↓ adipose mass 
↓ TG, LDL, TC 
↓ blood glucose level 
Chae et al., 
2016 
In vivo: STZ-induced 
white male rats 
Mangosteen rind extract for 7 d ↓ blood glucose level As’ari et al., 
2016 
In vivo: STZ-induced 
male rats 
Ethanolic extraction (by maceration) powder of G. 
mangostana pericarp; 50, 100, or 200 mg/kg BW 
administered orally as (1) single dose or (2) multiple 
doses for 14 d 
↓ blood glucose level 
↓ TG, LDL, VLDL, TC 
↓ SGOT, SGPT 
↓ serum creatinine, BUN, total protein 
Taher et al., 
2016 
In vivo: high fat diet-
induced for 3 w prior to 
STZ-induced male mice 
Xanthone at doses of 100, 200, or 400 mg/kg BW ↓ plasma MDA, kidney MDA 
↓ serum creatinine, BUN, kidney 
hypertrophy 
Karim et al., 
2017 
RCT 400 mg mangosteen fruit pulp extract titrated to 40% in 
α-and γ-mangostin (160 mg) per day for 26 w 
↑ insulin sensitivity: HOMA-IR 
decreased by 51.3% 
↑ HDL  
Watanabe et al., 
2018 




This review showed the potential pharmacological benefits of G. 
mangostana extracts and isolates in preventing and treating type-2 
DM. However, human studies using long-term biomarkers are 
lacking. To confirm the promising preventive and therapeutic effects 
of G. mangostana in type-2 DM, a clinical trial using long-term 
biomarkers is needed to evaluate the glycemic control effect, which 
is one important goal of therapy in DM.  
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